微生物组在阿尔茨海默病中的新兴作用。
The emerging role of the microbiome in Alzheimer's disease.
机构信息
Ann Romney Center for Neurologic Diseases, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, United States; Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden.
Ann Romney Center for Neurologic Diseases, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, United States; University of Massachusetts, Amherst, MA, United States.
出版信息
Int Rev Neurobiol. 2022;167:101-139. doi: 10.1016/bs.irn.2022.09.001. Epub 2022 Oct 13.
Alzheimer's disease (AD) is the most prevalent form of dementia and can be influenced by genetic and environmental factors. Recent studies suggest that the intestinal microbiota is altered in AD patients when compared to healthy individuals and may play a role in disease onset and progression. Aging is the greatest risk factor for AD, and age-related changes in the microbiota can affect processes that contribute to cognitive decline. The microbiota may affect AD by modulating peripheral and central immunity or by secreting factors that influence neurogenesis or neuronal cell death. Finally, probiotic and dietary interventions that target the microbiome may have therapeutic potential to prevent or treat AD.
阿尔茨海默病（AD）是最常见的痴呆症形式，它可以受到遗传和环境因素的影响。最近的研究表明，与健康个体相比，AD 患者的肠道微生物群发生了改变，并且可能在疾病的发生和进展中发挥作用。衰老时 AD 的最大危险因素，而微生物群的年龄相关性变化会影响导致认知能力下降的过程。微生物群可能通过调节外周和中枢免疫或通过分泌影响神经发生或神经元细胞死亡的因子来影响 AD。最后，针对微生物组的益生菌和饮食干预可能具有预防或治疗 AD 的治疗潜力。
Zotero 插件